Rexahn Pharma (RNN) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Rexahn Pharma (RNN) Tops Q3 EPS by 1c

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

November 3, 2015 9:02 AM EST

ROCKVILLE, Md., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent corporate and oncology pipeline developments.

Rexahn made important progress during the third quarter presenting new interim clinical data for Supinoxin and RX-3117 at an international medical conference, said Peter D. Suzdak, Ph.D., Chief Executive Officer.  We were particularly excited to see that these compounds appear to be safe and well... More